MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts

Cell Death and Disease

Volumn 3, Issue 8, 2012, Pages

  Rao Bindal, K ^a   Zhou, Z ^a   Kleinerman, E S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

C FLIP; Fas; Histone deacetylase inhibitors; Lipid rafts

Indexed keywords

DETERGENT; ENTINOSTAT; FAS LIGAND; FLICE INHIBITORY PROTEIN; MEMBRANE LIPID;

APOPTOSIS; ARTICLE; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIPID RAFT; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSITIZATION; UPREGULATION;

ANTIGENS, CD95; APOPTOSIS; BENZAMIDES; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; FAS LIGAND PROTEIN; HUMANS; MEMBRANE MICRODOMAINS; OSTEOSARCOMA; PYRIDINES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84865727534     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.101     Document Type: Article

References (32)

1. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178. (Pubitemid 24006113)
2. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335-343. (Pubitemid 26132532)
3. Worth LL, Lafleur EA, Jia SF, Kleinerman ES. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002; 9: 823-827.
4. Giuliano AE, Feig S, Eilber FR. Changing metastatic patterns of osteosarcoma. Cancer 1984; 54: 2160-2164. (Pubitemid 15210799)
5. Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther 2002; 9: 260-266. (Pubitemid 34205500)
6. Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv 2010; 23: 189-196.
7. Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL et al. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007; 13: 4503-4510. (Pubitemid 47219720)
8. Jia SF, Worth LL, Densmore CL, Xu B, Duan X, Kleinerman ES. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res, 2003; 9: 3462-3468. (Pubitemid 37082745)
9. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002; 296: 1635-1636. (Pubitemid 34579146)
10. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002; 21: 3704-3714. (Pubitemid 34787044)
11. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K et al. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001; 276: 20589-20596.
12. Chakrabandhu K, Herincs Z, Huault S, Dost B, Peng L, Conchonaud F et al. Palmitoylation is required for efficient Fas cell death signaling. EMBO J 2007; 26: 209-220. (Pubitemid 46094712)
13. Chaigne-Delalande B, Moreau JF, Legembre P. Rewinding the DISC. Arch Immunol Ther Exp 2008; 56: 9-14.
14. Bionda C, Athias A, Poncet D, Alphonse G, Guezguez A, Gambert P et al. Differential regulation of cell death in head and neck cell carcinoma through alteration of cholesterol levels in lipid rafts microdomains. Biochem Pharmacol 2008; 75: 761-772.
15. Koshkina NV, Rao-Bindal K, Kleinerman ES. Effect of the histone deacetylase inhibitor SNDX-275 on fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer 2011; 117: 3457-3467.
16. Rao-Bindal K, Kleinerman ES. The histone deacetylase inhibitor, MS-275, sensitizes osteosarcoma cells and osteosarcoma lung metastases to FasL-induced cell death by the downregulation c-FLIP. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research, Orlando Florida: Philadelphia (PA): AACR 2011 April 2-5.
17. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 1999; 17: 501-506. (Pubitemid 30182744)
18. Gordon N, Kleinerman ES. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res 2009; 152: 497-508.
19. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007; 5: 991-999. (Pubitemid 350070755)
20. Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005; 27:611-615. (Pubitemid 41697350)
21. Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004; 10: 8114-8119. (Pubitemid 39587553)
22. Lafleur EA, Jia SF, Worth LL, Zhou Z, Owen-Schaub LB, Kleinerman ES. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res 2001; 61: 4066-4071. (Pubitemid 32720972)
23. Escaffit F, Vaute O, Chevillard-Briet M, Segui B, Takami Y, Nakayama T et al. Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Mol Cell Biol 2007; 27: 554-567. (Pubitemid 46080124)
24. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007; 27: 4784-4795. (Pubitemid 47016131)
25. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274:1541-1548.
26. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388:190-195. (Pubitemid 27297457)
27. Lavrik IN. Regulation of death receptor-induced apoptosis induced via CD95/FAS and other death receptors. Mol Biol 2011; 45:173-179.
28. Beneteau M, Daburon S, Moreau JF, Taupin JL, Legembre P. Dominant-negative Fas mutation is reversed by down-expression of c-FLIP. Cancer Res 2007; 67:108-115. (Pubitemid 46142765)
29. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 2010; 42: 210-213.
30. Song JH, Tse MC, Bellail A, Phuphanich S, Khuri F, Kneteman NM et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res 2007; 67: 6946-6955. (Pubitemid 47105542)
31. Coligan JEKA, Margulies DH, Shevach EM, Strober W. Current Protocols in Immunology. In: Coico R: John Wiley & Sons I (ed). Related Isolation Procedures and Functional Assays, vol. 1, 1995.
32. Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005; 5:12.